Transplant Immunosuppression Management and COVID-19

Exp Clin Transplant. 2022 Jul;20(7):706-707. doi: 10.6002/ect.2020.0179. Epub 2020 Sep 17.

Authors

Dimitrios Giannis¹, Ioannis A Ziogas, Stepan M Esagian, Evangelia Matenoglou, Dimitrios Moris

Affiliation

¹ From the Institute of Health Innovations and Outcomes Research, Feinstein Institute for Medical Research, Manhasset, New York, USA.

PMID: 32967603
DOI: 10.6002/ect.2020.0179

No abstract available

Publication types

Letter
Comment

MeSH terms

COVID-19*
Humans
Immunosuppression Therapy
Immunosuppressive Agents / adverse effects
SARS-CoV-2
Transplant Recipients
Treatment Outcome

Substances

Immunosuppressive Agents